Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

被引：2

作者：

Timmerman, John ^{[1
]}

Lavie, David ^{[2
]}

Johnson, Nathalie A. ^{[3
]}

Avigdor, Abraham ^{[4
]}

Borchmann, Peter ^{[5
]}

Andreadis, Charalambos ^{[6
]}

Bazargan, Ali ^{[7
,8
]}

Gregory, Gareth P. ^{[9
]}

Keane, Colm ^{[10
]}

Tzoran, Inna ^{[11
]}

Vucinic, Vladan ^{[12
]}

Zinzani, Pier Luigi ^{[13
,14
]}

West, Rachel Marceau ^{[15
]}

Pillai, Pallavi ^{[15
]}

Marinello, Patricia ^{[15
]}

Herrera, Alex F. ^{[16
]}

机构：

[1] UCLA, Med Ctr, Los Angeles, CA USA

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada

[4] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[5] Univ Hosp Cologne, Cologne, Germany

[6] UCSF, San Francisco, CA USA

[7] Univ Melbourne, Melbourne, Vic, Australia

[8] St Vincents Hosp, Fitzroy, Vic, Australia

[9] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Australia

[10] Princess Alexandra Hosp, Brisbane, Qld, Australia

[11] Rambam Hlth Care Campus, Haifa, Israel

[12] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Cell Therapy & Hemostaseo, Leipzig, Germany

[13] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[14] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[15] Merck & Co Inc, Rahway, NJ USA

[16] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti-PD-1-refractory classical Hodgkin lymphoma (cHL): An updated analysis
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Peter, Borchmann
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Torzan, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth P.
Herrera, Alex F.
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Timmerman, John
BLOOD, 2023, 142
[3] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth P.
Herrera, Alex F.
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Nahar, Akash
Timmerman, John
BLOOD, 2022, 140 : 6540 - 6542
[4] A phase 1/2 study of favezelimab in combination with pembrolizumab for anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis
Timmerman, John
Lavie, David
Peter, Borchmann
Gregory, Gareth P.
Herrera, Alex Francisco
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Johnson, Nathalie A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Tsoran-Rosenthal, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Nahar, Akash
Herrera, Alex F.
BLOOD, 2022, 140
[6] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
Johnson, Nathalie A.
Lavie, David
Borchmann, Peter
Gregory, Gareth
Herrera, Alex Francisco
Minuk, Leonard
Vucinic, Vladan
Armand, Philippe
Avigdor, Abraham
Gasiorowski, Robin
Herishanu, Yair
Keane, Colm
Kuruvilla, John
Palcza, John
Pillai, Pallavi
Marinello, Patricia
Timmerman, John
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008
Lavie, David
Timmerman, John
Garcia-Sanz, Ramon
Kim, Won Seog
Kim, Tae Min
Avigdor, Abraham
Dierickx, Daan
Jagadeesh, Deepa
Molin, Daniel L.
Ozcan, Muhit
Sevindik, Omur Gokmen
Saeed, Hayder
Sidi, Yulia
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex F.
BLOOD, 2023, 142
[8] Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth
Keane, Colm
Inna, Tzoran
Vucinic, Vladan
Zinzani, Pier Luigi
Zhang, Hong
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma
Quero, L.
Gilardin, L.
Fumagalli, I.
Martin, V.
Guillerm, S.
Bauduceau, O.
Kirova, Y. M.
Hennequin, C.
Brice, P.
CANCER RADIOTHERAPIE, 2019, 23 (02): : 132 - 137
[10] Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study
Santoro, Armando
Johnson, Nathalie A.
Savage, Kerry J.
Avigdor, Abraham
Bazargan, Ali
Borchmann, Peter
Gasiorowski, Robin
Gregory, Gareth P.
Herishanu, Yair
Madan, Sumit
Minuk, Leonard
Musuraca, Gerardo
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Zinzani, Pier Luigi
BLOOD, 2023, 142

← 1 2 3 4 5 →